CYC
Asset Logo

Cyclopharm Limited

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’° Dividends

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 4.21%
Annual Growth

5 years average annual growth

πŸ’°

0.42%
Annual dividend yield

Based on the most recent dividend

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

3
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. The firm's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The firm uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The firm distributes its products in approximately 65 countries.

πŸ“ˆ Performance

Price History

+344.58%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’° Dividends

Payouts

πŸ’° Annual Dividend Yield*

0.42%

πŸ’° Annual Dividend Earnings Per $1,000 invested**

$4.17

πŸ’° Most Recent Dividend Franked Percentage Estimate

0.00%

πŸ’° Average Dividend Franked Percentage Estimate

82.00 %

πŸ’° Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Estimate your dividend

If you held

$

of CYC, your last dividend payment(s) would have been:

$ 20.83

on Mon Sep 11 2023

$ 33.33

on Tue Apr 04 2023

*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$0.01

0.00%

2022

$0.01

0.00%

2021

$0.01

0.00%

2020

$0.01

0.00%

2019

$0.01

0.00%

2018

$0.01

0.00%

2017

$0.01

0.00%

2016

$0.01

0.00%

2015

$0.01

100.00%

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$1.41

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in CYC

3

πŸ“Š Total Capital Earnings

$-457.29

πŸ”ƒ Average investment frequency

22 weeks

πŸ’΅ Average investment amount

$1,405

⏰ Last time a customer invested in CYC

69 days
CYC investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

33%

50k - 100k

Less than 50k

67%
πŸ‘Ά Age of investors

18 - 25

26 - 34

67%

35 - 90

33%
πŸ™‹ Legal gender of investors

Female

100%

Male

Pearlers who invest in CYC also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.85%

πŸ“Š Share price

$100.90 AUD

⛳️ DIVERSIFIED

πŸ‡¦πŸ‡Ί AUSTRALIA

🧱 MATERIALS

πŸ’Έ FINANCIALS

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

18.86%

πŸ“Š Share price

$57.74 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. The company is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).

πŸ™Œ Performance (5Yr p.a)

261.00%

πŸ“Š Share price

$22.41 AUD

🧬 BIOTECHNOLOGY

Argo Investments Ltd is a AU-based company operating in industry. The company is headquartered in Adelaide, South Australia. Argo Investments Limited is an Australia-based listed investment company (LIC). The firm manages a diversified portfolio of Australian shares with an internally managed business model. The principal activities of the Company include the investment of funds in Australian listed securities and short-term interest-bearing securities. Its investment objective is to maximize long-term shareholder returns through reliable fully franked dividend income and capital growth. Its investment portfolio comprises approximately 90 Australian companies from across a range of industries. Its portfolio includes investments in various sectors, such as materials, other financials, banks, healthcare, consumer staples, industrials, energy, consumer discretionary, property, utilities, listed investment companies, and others. Its subsidiary, Argo Service Company Pty Ltd, is engaged in providing investment management and administration operations for the Company.

πŸ™Œ Performance (5Yr p.a)

0.86%

πŸ“Š Share price

$8.70 AUD

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

12.86%

πŸ“Š Share price

$129.54 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

Want more shares? Try these...

Coventry Group Ltd. distributes and markets industrial products. The company is headquartered in Melbourne, Victoria. The firm supplies a range of fastening systems, cabinet hardware systems, hydraulics, lubrications, fire suppression, refueling systems and other products. The company principally distributes industrial products and services throughout Australia and New Zealand. The firm has two segments. Trade Distribution segment includes the importation, distribution and marketing of industrial fasteners, industrial hardware supplies and associated products, temporary fencing, and cabinet making hardware. Fluid Systems segment includes the design, manufacture, distribution, installation and maintenance of lubrication and hydraulic fluid systems and hoses. The Company’s brands include Cooper Fluid Systems, Torque Industries, H.I.S. Hose, Fluid Power Services, Nubco, Konnect Fastening Systems, Artia Cabinet Hardware Systems and Goudie Holdings Limited (GHL).

πŸ™Œ Performance (5Yr p.a)

0.31%

πŸ“Š Share price

$1.30 AUD

πŸ”¨ COMMERCIAL SERVICES & SUPPLIES

Catalyst Metals Ltd. engages in the acquisition, exploration and development of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-07-26. The firm owns the 40 kilometers (km) long Plutonic Gold Belt in Western Australia hosting the Plutonic gold mine and neighboring underexplored, high-grade resources. The Plutonic Gold Mine is located over 300 km northeast of Meekatharra in the mid-west region of Western Australia, at the northern end of the Eastern Gold Fields Province. The company also owns and operates the high-grade Henty Gold Mine in Tasmania, which lies within the 25 km Henty gold belt. The company also controls +75 km of strike length immediately north of the +22Moz Bendigo goldfield and home to high-grade, greenfield resources at Four Eagles. The company has interests in over 13 exploration licenses and two retention licenses along the Whitelaw and Tandarra Faults north of Bendigo and in other areas north of the Fosterville and Inglewood gold fields. Four Eagles Gold Project is situated along the Whitelaw Gold Corridor.

πŸ™Œ Performance (5Yr p.a)

6.22%

πŸ“Š Share price

$3.33 AUD

⛏️ MINING

Cygnus Metals Ltd. engages in the exploration and discovery of gold deposits in the Southwest Terrane of the Yilgarn Crato, Western Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2018-01-15. The firm is focused on advancing the Pontax Lithium Project (earning up to 70%), the Auclair Lithium Project and Sakami Lithium Project in the James Bay lithium district in Canada. In addition, the Company has rare earth elements (REE) and base metal projects at Bencubbin and Snake Rock in Western Australia. The Pontax Lithium Project is situated within the lithium province of James Bay in Northern Quebec, Canada. The Pontax Project covers approximately 183 kilometers (km2) landholding all located on category III lands. The Auclair Project covers over 417 km2 landholding located just 60 km north-east of the Whabouchi lithium mine. The Sakami Project is a landholding of 118 km2 covering the highly prospective La Grande greenstone belt. The company has approximately 1,750 km2 of granted tenements located over underexplored greenstone belts prospective for lithium, REEs, nickel, copper, platinum group elements (PGEs) and gold.

πŸ™Œ Performance (5Yr p.a)

60.00%

πŸ“Š Share price

$0.14 AUD

⛏️ MINING

πŸ“Š Share price

$0.22 AUD
Compare
Add to watchlist